Speaker: Alena Gros, PhD - Tumor Immunology and Immunotherapy Group - VHIO - Barcelona
Organizers: IRB Barcelona
Date: Friday 19 March 2021, 12.00h
Host: Lluís Ribas de Pouplana, PhD - IRB Barcelona
Open to predoctoral UPF students
Cancer immunotherapies exploit the immune system to attack cancer. Adoptive cell transfer (ACT), which consists in the administration of large numbers of antitumor T cells, can lead to durable antitumor responses in patients with metastatic melanoma and is currently being investigated for the treatment of solid cancers. T cells mediate specific tumor recognition through the interaction of the T-cell receptor with a peptide derived from a tumor antigen presented by the major histocompatibility complex. In this talk I present the challenges and current efforts to identify the personalized tumor antigens as well as the tumor-reactive TCR repertoire that will contribute to better understand and develop more effective immunotherapies for the treatment of solid cancers.